Periprocedural management of anticoagulation is a common clinical conundrum that
involves a multidisciplinary team, cuts across many specialties, and varies greatly between …

OBJECTIVE To estimate the 3-month cumulative incidence of thromboembolism (TE),
bleeding, and death among consecutive patients with nonvalvular atrial fibrillation (AF) who …

The optimal antithrombotic treatment regimen for patients with atrial fibrillation undergoing
percutaneous coronary intervention with stent implantation represents a challenge in clinical …

The periprocedural management of patients receiving chronic therapy with oral
anticoagulants (OACs), including vitamin K antagonists (VKAs) such as warfarin and direct …

A growing number of patients undergoing percutaneous coronary intervention (PCI) with
stent implantation also have atrial fibrillation. This poses challenges for their optimal …

Abstract In 2013, the European Heart Rhythm Association (EHRA) published a Practical
Guide on the use of non-VKA oral anticoagulants (NOACs) in patients with atrial fibrillation …

The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …

Atrial fibrillation (AF) is the most common cardiac arrhythmia. It was estimated to affect up to
6.1 million Americans in 2010, and since AF is more common with increasing age, it is …

Atrial fibrillation (AF) confers a substantial risk of mortality and morbidity from stroke and
thrombo-embolism, and this common cardiac arrhythmia represents a major healthcare …

Background Catheter ablation is recommended as a first-or second-line rhythm control
therapy for selected patients with atrial fibrillation (AF). There is a wide variability in the …